Anavex Life Sciences Corp (AVXL)

[OFP]

Nice recap and excellent references.

That being said, most of the data relates to S1R in general. Clearly its an exciting and developing field. However, there are many S1R agonists available and some have been tested in AD with marginal results. I disagree that A2-73 is a selective agonist...it clearly is not selective given the activity at other receptors as you listed. I also still do not see significant differences in Ca++ modulation. While some S1Rs are VGCC blockers I don't think that will be relevant for neuronal ER.

The Lahmy article does provide some theoretical basis for the one aspect that's already been discussed. Namely, the potential that S1R + muscarinic modulation in combination may provide a benefit that selective agents can not. I consider that fairly weak but its something at least and worth following. At the same time, those looking at the avalanche of excitement around S1R pharmacology as somehow specific to A2-73 should narrow their focus tremendously.